Sugen Inc. has raised $2.3 million in venture funding fromVenrock Associates and CW Group, the company announced.
The Redwood City, Calif., company is developing small-moleculedrugs based on cell surface receptors that act as regulators forcell physiology.
Financier Stephen Evans-Freke, founder of the company,previously raised about $4 million in seed funding through hiscorporate vehicle, International Technology InvestmentManagers.
(c) 1997 American Health Consultants. All rights reserved.